Founded in 1999, PELVIPHARM is a spin-off from the University of Versailles-Saint-Quentin-en-Yvelines (France) relying on multi-disciplinary talents (medical doctor, pharmaco-economist, veterinarian, pharmacists and PhDs) who deliver both high quality academic standards and reliable contract research services :
- Preclinical studies based on validated efficacy models including delivery of protocol development, study conduct, report, communication and peer-reviewed publication
- Guidance for selection of new chemical entities including testing with targeted assays according to potential mechanisms of action
- Identification of new properties or attributes supporting differentiation of medications within the class or between classes
- Advice in clinical development for new therapeutic indications or enhancements to address unmet medical need or significant commercial opportunities
PELVIPHARM has leading scientific and medical capabilities from unique expertise and experience in pathophysiology, pharmacology, clinical research and medical practice across a range of therapeutic areas including urology (BPH, OAB, NDO, SCI, SUI, IC …), sexual medicine (ED, PE, FSD …) and cardiovascular (Hypertension, Atherosclerosis, Myocardial Infarction …), metabolism and eating disorders (Metabolic Syndrome, Obesity, Diabetes ...)
PELVIPHARM can give you the unique expertise and the experience of a team gathered over the years.
News and next meetings
Pelvipharm wishes you the very best for the new year and a healthy prosperous 2018 !...
Bio-Europe Spring in Barcelona, March 2017
Pelvipharm will be represented by Rana Assaly at the next BIO-Europe Spring meeting in Barcelona, Ma......
Future presentation at the EAU 2017
Pelvipharm at the EAU (European Association of Urology) in London, UK, 24-28 March 2017. Pelvipha......
Recently accepted paper in Ann. Neurol.
Human spinal generator of ejaculation Chéhensse C, Facchinetti P, Bahrami S, Andrey P, Soler J-M, C......
Latest website updates
New abstract/poster available for download
"Added Benefit of Empagliflozin: Improvement of Erectile Dysfunction in Diabetic Type 2 Rats" presented at ADA 2015 in Boston, MA, USA, June 5-9, 2015.
New experimental skills developed
New model developped